FindTrial
Sign In

Chemotherapy or Surgery? The New Test That Helps Your Doctor Decide the Best Way Forward.

VALIDATION OF BIOMARKER PANEL QBM BrCa 1 IN PRE TREATMENT BIOPSIES TO PREDICT NEO ADJUVANT CHEMOTHERAPEUTIC RESPONSE IN TRIPLE NEGATIVE BREAST CANCER - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/02/103319
Enrollment
20
Registered
2026-02-09
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: C50- Malignant neoplasm of breast

Interventions

Intervention1: Nil: Nil

Sponsors

Quantbiomed Private Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Patients with early stage triple-negative breast cancer

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Pathological complete response and residual cancer burden in post-surgical tissues after completing neo-adjuvant chemotherapyTimepoint: At surgery, 3 to 8 weeks after the last cycle of neo-adjuvant chemotherapy (18 to 24 weeks after starting the first cycle after an initial diagnosis)—

Secondary

MeasureTime frame
NILTimepoint: NIL—

Countries

India

Contacts

Public ContactProf.(Dr.) Arup Chakraborty

Medical College Kolkata

dr.arupchakraborty@gmail.com

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Mar 14, 2026